Engineered CAR-T cells co-expressing IL-7 and CCL21 exhibited increased anti-tumor efficacy due to significantly improved survival and infiltration of both the CAR-T cells and DCs in the TME (41). The gene discussed is CCL21; the disease is neoplasm.